SCHEMBL5556335

SCHEMBL5556335

CC(C)C1Oc2ccc(Br)cc2C(C(=O)NC(C)(C)C)N(Cc2cccnc2)C1=O

nearest known ligand 0.39

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
MDM2 Q00987 2/20 0.39
RXFP1 Q9HBX9 3/20 0.37
PPARG P37231 1/20 0.37
NCOR2 Q9Y618 1/20 0.37
TDP1 Q9NUW8 1/20 0.37
MEN1 O00255 1/20 0.36
KMT2A Q03164 1/20 0.36
RIPK1 Q13546 1/20 0.36
HDAC1 Q13547 1/20 0.35
HDAC2 Q92769 1/20 0.35
HDAC8 Q9BY41 1/20 0.35
HDAC6 Q9UBN7 1/20 0.35
POLB P06746 2/20 0.34
ALDH1A1 P00352 4/20 0.34
KDM4E B2RXH2 1/20 0.34
NPSR1 Q6W5P4 1/20 0.34
C3AR1 Q16581 1/20 0.34
XIAP P98170 1/20 0.33
HTT P42858 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5562904 0.91 ALDH1A1 (0.43) RXFP1PPARGNCOR2TDP1MEN1
SCHEMBL5562273 0.89 TDP1 (0.43) TDP1HDAC1HDAC2HDAC8HDAC6
SCHEMBL5556179 0.88 MDM2 (0.43) MDM2RXFP1PPARGNCOR2MEN1
SCHEMBL5561530 0.88 MDM2 (0.41) MDM2RXFP1TDP1MEN1KMT2A
SCHEMBL5555742 0.87 ALOX5 (0.40) MDM2RXFP1PPARGNCOR2TDP1
SCHEMBL5561526 0.86 CASP1 (0.43) MDM2C3AR1HTT
SCHEMBL5561834 0.84 ALDH1A1 (0.44) RXFP1TDP1MEN1KMT2APOLB
SCHEMBL5556744 0.83 KCNA5 (0.32) TDP1MEN1KMT2AHDAC1HDAC6
SCHEMBL5561772 0.82 KCNA5 (0.38)
SCHEMBL5563325 0.82 MAPT (0.38) TDP1MEN1KMT2APOLBALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1631296-B1 2,3,4,5-TETRAHYDROBENZO¬F|¬1,4|OXAZEPINE-5-CARBOXYLIC ACID AMIDE DERIVATIVES AS GAMMA-SECRETASE INHIBITORS FOR THE TREATMENT OF ALZHEIMER'S DISEASE HOFFMANN LA ROCHE (CH) 2007-04-25 EP disclosed
US-7060698-B2 Benzoxazepinone derivatives HOFFMANN-LA ROCHE INC. (US) 2006-06-13 US disclosed
US-20040235819-A1 5-alkylaminocarbonyl-substituted, e.g., 4-(1-benzyl-piperidin-4-yl)-2-isopropyl-3-oxo-2,3,4,5-tetrahydro-benzo[f][1,4]oxazepine-5-carboxylic acid tert-butylamide; gamma -secretase inhibitors for the treatment of Alzheimer's disease. HOFFMANN-LA ROCHE INC. 2004-11-25 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040235819-A1 5-alkylaminocarbonyl-substituted, e.g., 4-(1-benzyl-piperidin-4-yl)-2-isopropyl-3-oxo-2,3,4,5-tetrahydro-benzo[f][1,4]oxazepine-5-carboxylic acid tert-butylamide; gamma -secretase inhibitors for the treatment of Alzheimer's disease. BACE1, BACE2, PSEN1 MDM2 4003/4885RXFP1 1593/4885PPARG 430/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.